CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing cost-effective chiral catalysts for the asymmetric reduction of pharmaceuticals, using first-row base metals. It aims to address challenges in producing enantiopure compounds efficiently while training researchers in sustainable practices.
A number of methods exist for the production of enantiopure pharma intermediates.
Among them, classical resolution by crystallization is the least efficient and most used one, while asymmetric catalysis, arguably the most efficient, is much less used.
This paradox is due to a number of factors, such as: 1.
High cost of the catalyst. 2.
Lack of scope. 3.
Time-to-market pressure.
In this project we will investigate solutions to problems 1 and 2.
We will develop new chiral catalysts for asymmetric…
UNIVERSITA DEGLI STUDI DI MILANO
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, SITTARD
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
